2 months ago
22
Aaron McDade
Fri, Apr 25, 2025, 9:49 AM 1 min read
In This Article:
Rob Stothard / Bloomberg via Getty Images
-
AbbVie's first-quarter income and adjusted net per stock topped estimates.
-
The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.
-
However, the institution noted its concern could beryllium impacted by tariffs that President Trump has said helium plans to spot connected the industry.
AbbVie (ABBV) connected Friday reported first-quarter results that came successful supra analysts' estimates, and lifted its full-year nett guidance.
The drugmaker generated adjusted earnings per stock (EPS) of $2.46 connected gross that roseate 8% year-over-year to $13.34 billion. Analysts polled by Visible Alpha expected $2.40 and $12.92 billion, respectively.
Sales of Skyrizi and Rinvoq soared much than 70% and 57%, respectively, but those of Humira fell by half. The 3 immunology drugs made up astir fractional of AbbVie's Q1 gross astatine a combined $6.26 billion.
AbbVie lifted its full-year adjusted EPS nett forecast to a scope of $12.09 to $12.29 from the anterior $11.99 to $12.19. The institution said its existent outlook is "based connected the existing commercialized situation and does not bespeak immoderate commercialized argumentation shifts, including pharmaceutical assemblage tariffs, that could impact AbbVie's business."
President Trump has said that helium plans to spot tariffs connected the cause industry, which were exempted from the archetypal circular of tariffs announced earlier this month.
AbbVie shares, which entered the time 1.5% higher this year, were up astir 3% aboriginal Friday afternoon.
Read the archetypal nonfiction connected Investopedia
English (CA) · 
English (US) · 
Spanish (MX) ·